Avacopan
- 15 April 2022
- journal article
- review article
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 58 (2) , 134-142
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated VasculitisArthritis & Rheumatology, 2021
- ANCA-Associated Vasculitis: An UpdateJournal of Clinical Medicine, 2021
- Avacopan for the Treatment of ANCA-Associated VasculitisNew England Journal of Medicine, 2021
- Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated VasculitisACR Open Rheumatology, 2020
- Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and functionBiochemical Pharmacology, 2020
- Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 TrialJMIR Research Protocols, 2020
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated VasculitisJournal of the American Society of Nephrology, 2017
- Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPLOS ONE, 2016
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisAnnals of the Rheumatic Diseases, 2016